China Medical Technologies

China Medical Technologies was a prominent medical device company based in China that specialized in the development and manufacture of advanced diagnostic systems. The company's core business revolved around two primary technology platforms: Enhanced Chemiluminescence Immunoassay (ECLIA) and Fluorescence In Situ Hybridization (FISH). These systems were used for a wide range of clinical applications, including oncology, prenatal screening, and infectious disease testing. At its peak, the company was listed on the NASDAQ and was considered a leader in the Chinese molecular diagnostics market. However, the company collapsed in 2012 following allegations of a massive fraud scheme orchestrated by its top executives, leading to its delisting and subsequent liquidation.